193 related articles for article (PubMed ID: 21331691)
1. Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy.
Akaza E; Yuzawa M; Mori R
Jpn J Ophthalmol; 2011 Jan; 55(1):39-44. PubMed ID: 21331691
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal ranibizumab combined with verteporfin photodynamic therapy for treating polypoidal choroidal vasculopathy.
Lee YH; Lee EK; Shin KS; Lee KM; Kim JY
Retina; 2011; 31(7):1287-93. PubMed ID: 21386762
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy.
Lai TY; Lee GK; Luk FO; Lam DS
Retina; 2011 Sep; 31(8):1581-8. PubMed ID: 21610566
[TBL] [Abstract][Full Text] [Related]
4. Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy.
Otani A; Sasahara M; Yodoi Y; Aikawa H; Tamura H; Tsujikawa A; Yoshimura N
Am J Ophthalmol; 2007 Jul; 144(1):7-14. PubMed ID: 17467649
[TBL] [Abstract][Full Text] [Related]
5. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab.
Tomita K; Tsujikawa A; Yamashiro K; Ooto S; Tamura H; Otani A; Nakayama Y; Yoshimura N
Am J Ophthalmol; 2012 Jan; 153(1):68-80.e1. PubMed ID: 21907965
[TBL] [Abstract][Full Text] [Related]
6. [Polypoidal choroidal vasculopathy].
Yuzawa M
Nippon Ganka Gakkai Zasshi; 2012 Mar; 116(3):200-31; discussion 232. PubMed ID: 22568102
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing visual outcome of polypoidal choroidal vasculopathy one year after photodynamic therapy.
Mori R; Yuzawa M; Lee Z; Haruyama M; Akaza E
Graefes Arch Clin Exp Ophthalmol; 2010 Sep; 248(9):1233-9. PubMed ID: 20352440
[TBL] [Abstract][Full Text] [Related]
8. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients.
Gomi F; Ohji M; Sayanagi K; Sawa M; Sakaguchi H; Oshima Y; Ikuno Y; Tano Y
Ophthalmology; 2008 Jan; 115(1):141-6. PubMed ID: 17582498
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy.
Wakabayashi T; Gomi F; Sawa M; Tsujikawa M; Nishida K
Br J Ophthalmol; 2012 Mar; 96(3):394-9. PubMed ID: 21719568
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy.
Akaza E; Mori R; Yuzawa M
Retina; 2008 May; 28(5):717-22. PubMed ID: 18463515
[TBL] [Abstract][Full Text] [Related]
11. Photodynamic therapy with verteporfin in polypoidal choroidal vasculopathy: results after 3 years of follow-up.
Leal S; Silva R; Figueira J; Cachulo ML; Pires I; de Abreu JR; Cunha-Vaz JG
Retina; 2010 Sep; 30(8):1197-205. PubMed ID: 20827139
[TBL] [Abstract][Full Text] [Related]
12. Marked vascular changes of polypoidal choroidal vasculopathy after photodynamic therapy.
Wakabayashi T; Gomi F; Sawa M; Tsujikawa M; Tano Y
Br J Ophthalmol; 2008 Jul; 92(7):936-40. PubMed ID: 18577645
[TBL] [Abstract][Full Text] [Related]
13. Factors predictive of visual acuity outcomes 1 year after photodynamic therapy in Japanese patients with polypoidal choroidal vasculopathy.
Hikichi T; Ohtsuka H; Higuchi M; Matsushita T; Ariga H; Kosaka S; Matsushita R; Takami K
Retina; 2011 May; 31(5):857-65. PubMed ID: 21124252
[TBL] [Abstract][Full Text] [Related]
14. Role of photodynamic therapy in polypoidal choroidal vasculopathy.
Akaza E; Yuzawa M; Matsumoto Y; Kashiwakura S; Fujita K; Mori R
Jpn J Ophthalmol; 2007; 51(4):270-7. PubMed ID: 17660987
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.
Gomi F; Sawa M; Wakabayashi T; Sasamoto Y; Suzuki M; Tsujikawa M
Am J Ophthalmol; 2010 Jul; 150(1):48-54.e1. PubMed ID: 20609707
[TBL] [Abstract][Full Text] [Related]
16. One-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.
Yamashita A; Shiraga F; Shiragami C; Ono A; Tenkumo K
Am J Ophthalmol; 2010 Mar; 149(3):465-71.e1. PubMed ID: 20042180
[TBL] [Abstract][Full Text] [Related]
17. One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy.
Cheng CK; Peng CH; Chang CK; Hu CC; Chen LJ
Retina; 2011 May; 31(5):846-56. PubMed ID: 21317837
[TBL] [Abstract][Full Text] [Related]
18. Photodynamic therapy, ranibizumab, and ranibizumab with photodynamic therapy for the treatment of polypoidal choroidal vasculopathy.
Rouvas AA; Papakostas TD; Ntouraki A; Douvali M; Vergados I; Ladas ID
Retina; 2011 Mar; 31(3):464-74. PubMed ID: 20948458
[TBL] [Abstract][Full Text] [Related]
19. Clinical features and follow-up results of pulsating polypoidal choroidal vasculopathy treated with photodynamic therapy.
Byeon SH; Lew YJ; Lee SC; Kwon OW
Acta Ophthalmol; 2010 Sep; 88(6):660-8. PubMed ID: 19563374
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
Jain P; Anantharaman G; Gopalakrishnan M; Goyal A
Indian J Ophthalmol; 2018 Aug; 66(8):1119-1127. PubMed ID: 30038155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
